March 22, 2018 / 8:38 PM / 4 months ago

BRIEF-Ligand Pharmaceuticals Says ‍Entered Amendment No. 5 To Sublicense Agreement With Retrophin

March 22 (Reuters) - Ligand Pharmaceuticals Inc:

* LIGAND PHARMACEUTICALS SAYS ‍ON MARCH 20, CO ENTERED INTO AMENDMENT NO. 5 TO SUBLICENSE AGREEMENT, DATED FEB 16, 2012 WITH RETROPHIN, INC- SEC FILING​

* LIGAND - PURSUANT TO AMENDMENT, RETROPHIN PAID CO $4.6 MILLION, WHICH COVERED AMOUNT DUE UPON INITIATION OF FIRST PHASE 3 TRIAL FOR SPARSENTAN​

* LIGAND -CO TO PAY $3 MILLION OF AMOUNT PAID BY RETROPHIN TO BRISTOL-MYERS SQUIBB PURSUANT TO AGREEMENT DATED MAY 27 2006 BETWEEN CO, BRISTOL-MYERS SQUIBB​ Source text - bit.ly/2HTmNbd Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below